Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antihypertensive Agents Clear all
Completed No phase listed Observational

Ambulatory Blood Pressure Monitoring in Children

NCT01070342
View directory record Official record
Conditions
Blood Pressure
Interventions
Spacelabs 90217
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Little Rock, Arkansas • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Jun 10, 2026, 2:12 PM EDT
Completed No phase listed Observational

Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock

NCT02876341
View directory record Official record
Conditions
Atrial Fibrillation, Septic Shock
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

NCT00330369
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans

NCT03179163
View directory record Official record
Conditions
Hypertension,Essential
Interventions
Captopril Pill, Enalapril Pill, Hydrochlorothiazide
Drug
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jun 10, 2026, 2:12 PM EDT
Withdrawn Phase 4 Interventional

The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy

NCT01042574
View directory record Official record
Conditions
Hypertension, Intracranial Hemorrhage, Subarachnoid Hemorrhage
Interventions
Clevidipine butyrate
Drug
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

NCT02439749
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Symplicity Spyral™ multi-electrode renal denervation system, Sham Procedure
Device · Procedure
Lead sponsor
Medtronic Vascular
Industry
Eligibility
20 Years to 80 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
30
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study

NCT01409434
View directory record Official record
Conditions
Drug Induced Hyperglycemia, Secondary Hyperlipidemia
Interventions
Oral Glucose Tolerance Test
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Jun 10, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.

NCT05676476
View directory record Official record
Conditions
Preeclampsia, Gestational Hypertension, Hypertensive Disorder of Pregnancy
Interventions
Antihypertensive treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 49 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Morning Versus Evening Dosing of Antihypertensive Medications: A Pilot Study to Assess Feasibility and Efficacy

NCT01965847
View directory record Official record
Conditions
Hypertension
Interventions
Medication therapy management
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
19 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Jun 10, 2026, 2:12 PM EDT
Recruiting Phase 3 Interventional

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

NCT05551104
View directory record Official record
Conditions
Postpartum Complication, Maternal Hypertension, High Blood Pressure
Interventions
Oral Nifedipine, Oral Labetalol
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril

NCT01258764
View directory record Official record
Conditions
Hypertension, Grade 1, Hypertension Treatment, N of 1 Study Design, Hypertension
Interventions
Lisinopril, Hydrochlorothiazide
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Mobile, Alabama • Tucson, Arizona • Inglewood, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

NCT00439738
View directory record Official record
Conditions
Hypertension
Interventions
HCTZ + Amlodipine, Valsartan/HCTZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Muscle Shoals, Alabama • Westlake Village, California • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Jun 10, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Intensive Postpartum Antihypertensive Treatment

NCT05687344
View directory record Official record
Conditions
Hypertensive Disorder of Pregnancy
Interventions
Nifedipine ER
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Improving Antihypertensive Medication Adherence

NCT01296594
View directory record Official record
Conditions
High Blood Pressure, Substance Abuse
Interventions
Usual Care, Contingency Management
Other · Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of RMJH-111b to Treat Essential Hypertension

NCT02822222
View directory record Official record
Conditions
Essential Hypertension
Interventions
Magnesium citrate, tribasic anhydrous soft gelatin capsule, Placebo soft gelatin capsule
Drug
Lead sponsor
RMJ Holdings, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Jun 10, 2026, 2:12 PM EDT
Recruiting Phase 4 Interventional

PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy

NCT06915792
View directory record Official record
Conditions
Postpartum Hypertension (PPHT)
Interventions
Labetalol, Nifedipine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Implementing Evidence Based Treatment of Hypertension

NCT00265538
View directory record Official record
Conditions
Hypertension
Interventions
Patient educational letter to engage provider in hypertension rx discussion, Financial incentive (Arms B and C) and health educator phone call (Arm C)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Iowa City, Iowa • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

NCT01953432
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

NCT00093249
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Jun 10, 2026, 2:12 PM EDT
Completed No phase listed Observational

Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data

NCT04354376
View directory record Official record
Conditions
Hypertension
Interventions
Loop diuretics, thiazides, dihydropyridines, Telmisartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years and older
Enrollment
40,048 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 4 Interventional

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

NCT04412096
View directory record Official record
Conditions
Glaucoma, OHT - Ocular Hypertension
Interventions
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jun 10, 2026, 2:12 PM EDT